KATIE Price’s 28 stone son faces more surgery after going on Ozempic jabs. And Harvey’s terrified mum fears the 22-year-old may die of a heart attack without help. Coming soon: Katie ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

STRUGGLING to keep up with her two young children and dreading her own reflection in the mirror, Emma Lasenby knew something ...

Robert Vilahamn spoke to the media at Hotspur Way on Friday afternoon, ahead of our Barclays Women’s Super League clash against Manchester United at Tottenham Hotspur Stadium on Sunday (6.45pm UK).

Ophthalmic complications were observed in patients using semaglutide and tirzepatide, but a causal link was not established. The study included nine patients, with conditions like nonarteritic ...